课题基金 / 基金详情

Mechanisms of Probiotics in Alcoholic Liver Disease

Mechanisms of Probiotics in Alcoholic Liver Disease
益生菌治疗酒精性肝病的机制
批准号:
9325388
负责人:
WENKE FENG
金额:
$30.8万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-09-15 至 2020-08-31

项目摘要

项目成果

WENKE FENG的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
 DESCRIPTION (provided by applicant): Severe alcoholic liver disease (ALD) has a high morbidity and mortality. Recent studies demonstrated that probiotics reversed alcohol-induced hepatic steatosis and inflammation, and improved liver enzymes in animal models and in patients. Our laboratory showed that administration of a probiotic strain, Lactobacillus rhamnosus Gorbach-Goldin (LGG), significantly improved liver enzymes and histology in alcohol treated mice. However, the beneficial mechanisms of action of LGG, either in viable bacteria form or in culture supernatant form, are not clear. Our overall hypothesis is that LGG increases intestinal cathelicidin-related antimicrobial peptide (CRAMP), intestinal trefoil factor (ITF) expression and intestinal short chain fatty acids (SCFAs), leading to improved gut microbiota homeostasis, intestinal barrier integrity and hepatic fat metabolism, and these are likely the mechanisms by which LGG supplementation attenuates alcohol induced liver injury. We evaluate mechanisms of LGG action with 4 specific aims: Aim 1 will determine the role of CRAMP in the alcohol-mediated changes in gut microbiota and the role of CRAMP in the beneficial effects of LGG in experimental ALD. We will use CRAMP knockout mouse model of ALD to determine the role of CRAMP and LGG in alcohol-induced changes in gut microbiota using a metagenomic approach. Aim 2 will determine the role of LGG in promoting ITF expression and evaluate whether ITF positively modulates intestinal tight junctions as a mechanism for improved intestinal barrier integrity in experimental ALD. We will use an ITF-secreting goblet cell line to evaluate the role of LGG in the production of ITF and the role of ITF in the modulation of intestinal tight junctions in an epithelial cell line. We will also examine th strategy that oral administration of recombinant human ITF attenuates alcohol-induced intestinal barrier and liver injury. Aim 3 will determine the role and mechanisms of butyric acid in the beneficial effects of LGG on intestinal tight junctions in experimental ALD. A metabolomics approach will be used to analyze the changes in SCFAs induced by alcohol and LGG intervention in the intestinal lumen. We will explore the potential mechanisms underlying the role of butyric acid in the regulation of occludin expression involving intestinal histone deacetylases (HDACs), miR122a, and HIF--mediated signaling in vitro and in vivo. Aim 4 will evaluate and compare the effectiveness of LGG supernatant (LGGs) with viable LGG (vLGG) and heat-inactivated LGG (hiLGG) in the prevention/therapy of ALD in mouse models. These three LGG preparations will be tested for the effectiveness in the prevention/therapy of ALD in three experimental models of ALD of steatosis, steatohepatitis and fibrosis. This study will have a major impact on the development of probiotic-based new therapeutic strategy for the prevention and treatment of ALD.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Cannabidiol as a treatment for alcoholic liver disease
  • 批准号:
    10753729
  • 项目类别:
  • 资助金额:
    $41.13万
  • 财政年份:
    2023
  • 负责人:
    WENKE FENG
  • 依托单位:
Intestine FXR activation by LGG-derived nanoparticles in alcohol-associated liver disease
  • 批准号:
    10531712
  • 项目类别:
  • 资助金额:
    $53.2万
  • 财政年份:
    2022
  • 负责人:
    WENKE FENG
  • 依托单位:
Intestine FXR activation by LGG-derived nanoparticles in alcohol-associated liver disease
  • 批准号:
    10794805
  • 项目类别:
  • 资助金额:
    $51.98万
  • 财政年份:
    2022
  • 负责人:
    WENKE FENG
  • 依托单位:
Probiotic-derived nano-particles in alcoholic liver disease
  • 批准号:
    10056416
  • 项目类别:
  • 资助金额:
    $8.07万
  • 财政年份:
    2016
  • 负责人:
    WENKE FENG
  • 依托单位:
海外基金